commencement of phase 3 trials, page-4

Furthermore; how dare they hold shareholders to ransom with such inconsistent drivel?

I participated in the rights issue at 53c. The funds were to be used for commencement of the PhIII trial, even though they did not have the full amount required.

" the commencement of the single Phase III trial for HA-Irenotecan will be the primary use of the proceeds"

All actions and communications from management recently seem to be constructed purely to excuse or justify previous poor decisions.

Enough is enough. We have enough money to commence the trial irrespective of what happens to the 2nd tranche.

Cut the crap.